NasdaqGS:PODDMedical Equipment
Is Insulet (PODD) Undervalued As Legal Actions Raise New Questions Over Omnipod Risks?
Multiple legal actions tied to alleged safety and disclosure issues around Insulet (PODD) and its Omnipod insulin delivery products have put the stock under closer scrutiny for many investors.
See our latest analysis for Insulet.
Against this backdrop of product safety concerns and fresh lawsuits, Insulet’s share price has had mixed momentum, with a 90 day share price return of 10.27% but a year to date share price decline of 41.04% and a 1 year total shareholder return decline of 40.63%.
If...